Biohaven Ltd. (BHVN)

US — Healthcare Sector
Peers: IMNM  INBX  AGE  ICVX  DAWN  TERN  XFOR  INZY  MREO  APLS  BPMC  CERE  MRTX  AMLX  KYMR  RVMD  CCCC  AGIO  NRIX 

Automate Your Wheel Strategy on BHVN

With Tiblio's Option Bot, you can configure your own wheel strategy including BHVN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol BHVN
  • Rev/Share 0.0
  • Book/Share 2.5455
  • PB 5.6807
  • Debt/Equity 0.1187
  • CurrentRatio 2.3334
  • ROIC -3.1339

 

  • MktCap 1476547126.0
  • FreeCF/Share -6.3664
  • PFCF -2.2751
  • PE -1.6589
  • Debt/Assets 0.0671
  • DivYield 0
  • ROE -2.5707

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 1
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Downgrade BHVN RBC Capital Mkts Outperform Sector Perform -- $21 May 19, 2025
Initiation BHVN Deutsche Bank -- Buy -- $65 Feb. 11, 2025
Initiation BHVN Jefferies -- Buy -- $57 Sept. 16, 2024

News

Biohaven: NDA Review Of Troriluzole Isn't Only 2025 Catalyst On Deck
BHVN
Published: February 11, 2025 by: Seeking Alpha
Sentiment: Positive

Biohaven's NDA for Troriluzole in spinocerebellar ataxia was accepted by the FDA with Priority Review, potentially leading to approval in Q3 2025. BHV-7000, a selective Kv7 activator, is being studied for bipolar disorder and MDD, with data expected in 2025. The global major depressive disorder treatment market is expected to reach $14.96 billion by 2032.

Read More
image for news Biohaven: NDA Review Of Troriluzole Isn't Only 2025 Catalyst On Deck

About Biohaven Ltd. (BHVN)

  • IPO Date 2022-09-23
  • Website https://www.biohaven.com/
  • Industry Biotechnology
  • CEO Dr. Vladimir Coric M.D.
  • Employees 256
Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.